Genmab Announces that Janssen has Received Positive CHMP Opinion for RYBREVANT® (amivantamab) for Patients with Advanced Non-sm
15/10 19:46
Janssen- Cilag International NV (Janssen) received a positive CHMP opinion recommending conditional marketing authorization of amivantamab in Europe for the treatment of adult patients with advanced non-small cell lung cancer with activating epidermal growth factor receptor e xon...